EPITOPIC GmbH was founded to commercialize a novel approach in collecting and analyzing peptide phage display data. What started as a ‘weird’ idea by one of the founders already 20 years ago, but lacked today’s NGS and computing capabilities, has been developed into a fully validated and rapid method to determine the epitopes of antibodies.
EPITOPIC GmbH started on the basis of results from 4 years of collaboration between PolyQuant GmbH in Bad Abbach and the Fraunhofer Institute for Cell Therapy and Immunology (IZI) in Leipzig, Germany. EPITOPIC and IZI have cross licensed essential technologies.
In collaboration with the Fraunhofer IZI new emerging applications include the immunome characterization of allergy patients, vaccine responses or anti-drug antibodies. Therefore, the exploitation of the broad application range of our technologies has just begun. New business areas regarding immunome characterization will be added to EPITOPIC’s portfolio soon.
Header – highlighted epitope sequence (S)IYTSDnyxeE of anti-mouse CD184 antibody/CXCR4 (BD Pharmingen, Nr. 551966) in CD184 structure